Valuation: Evofem Biosciences, Inc.

Market Cap 928K 806K 751K 689K 1.3M 88.56M 1.32M 8.85M 3.47M 44.09M 3.48M 3.41M 148M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.34M 48.11M 44.78M 41.11M 77.64M 5.28B 78.84M 528M 207M 2.63B 208M 203M 8.82B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+7.59%
1 week+3.66%
Current month+21.43%
1 month-3.41%
3 months+23.19%
6 months-3.41%
Current year-10.53%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.007
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.43
5 years 0
Extreme 0.0008
1,826.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap.
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+7.59%+3.66%-6.59%-98.07% 928K
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -0.43%-1.09%+22.77%+28.36% 341.89B
Weighted average by Cap. -1.00%-2.02%+36.14%+71.90%

Financials

2024 2025
Net sales 19.36M 16.83M 15.67M 14.38M 27.16M 1.85B 27.58M 185M 72.48M 920M 72.72M 71.12M 3.09B 20.18M 17.55M 16.33M 14.99M 28.31M 1.93B 28.75M 192M 75.55M 959M 75.8M 74.13M 3.22B
Net income -8.86M -7.7M -7.17M -6.58M -12.43M -846M -12.62M -84.5M -33.16M -421M -33.27M -32.54M -1.41B 391K 340K 316K 290K 549K 37.33M 557K 3.73M 1.46M 18.58M 1.47M 1.44M 62.31M
Net Debt 45.84M 39.85M 37.09M 34.05M 64.31M 4.38B 65.3M 437M 172M 2.18B 172M 168M 7.3B 54.42M 47.3M 44.03M 40.43M 76.34M 5.19B 77.52M 519M 204M 2.59B 204M 200M 8.67B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
31/07/26 US$0.007000 -1.41% 227,491
30/07/26 US$0.007100 -6.58% 620,854
29/07/26 US$0.007600 +0.40% 41,922
28/07/26 US$0.007570 -4.18% 133,706
27/07/26 US$0.007900 -3.66% 31,442

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock